2003结肠癌筛查和监控临床指南(英文)-美国胃肠病协会.doc_第1页
2003结肠癌筛查和监控临床指南(英文)-美国胃肠病协会.doc_第2页
2003结肠癌筛查和监控临床指南(英文)-美国胃肠病协会.doc_第3页
2003结肠癌筛查和监控临床指南(英文)-美国胃肠病协会.doc_第4页
2003结肠癌筛查和监控临床指南(英文)-美国胃肠病协会.doc_第5页
已阅读5页,还剩9页未读, 继续免费阅读

下载本文档

版权说明:本文档由用户提供并上传,收益归属内容提供方,若内容存在侵权,请进行举报或认领

文档简介

Colorectal cancer screening and surveillance: Clinical guidelines and rationaleUpdate based on new evidenceAbstractWe have updated guidelines for screening for colorectal cancer. The original guidelines were prepared by a panel convened by the U.S. Agency for Health Care Policy and Research and published in 1997 under the sponsorship of a consortium of gastroenterology societies. Since then, much has changed, both in the research rature and in the clinical context. The present report summarizes new developments in this field and suggests how they should change practice. As with the previous version, these guidelines offer screening options and encourage the physician and patient to decide together which is the best approach for them. The guidelines also take into account not only the effectiveness of screening but also the risks, inconvenience, and cost of the various approaches. These guidelines differ from those published in 1997 in several ways: we recommend against rehydrating fecal occult blood tests; the screening interval for double contrast barium enema has been shortened to 5 years; colonoscopy is the preferred test for the diagnostic investigation of patients with findings on screening and for screening patients with a family history of hereditary nonpolyposis colorectal cancer; recommendations for people with a family history of colorectal cancer make greater use of risk stratification; and guidelines for genetic testing are included. Guidelines for surveillance are also included. Follow-up of postpolypectomy patients relies now on colonoscopy, and the first follow-up examination has been lengthened from 3 to 5 years for low-risk patients. If this were adopted nationally, surveillance resources could be shifted to screening and diagnosis. Promising new screening tests (virtual colonoscopy and tests for altered DNA in stool) are in development but are not yet ready for use outside of research studies. Despite a consensus among expert groups on the effectiveness of screening for colorectal cancer, screening rates remain low. Improvement depends on changes in patients attitudes, physicians behaviors, insurance coverage, and the surveillance and reminder systems necessary to support screening programs. GASTROENTEROLOGY 2003;124:544-560Eight years ago, an expert panel was assembled by the U.S. Agency for Health Care Policy and Research to prepare clinical practice guidelines for colorectal cancer screening and accompanying rationale based on the best available evidence. The Panel was convened by a consortium of gastroenterology societies, all of which provided logistic support throughout and financial support during the latter part of the Panels work.The Panels report, published in 1997,1 highlighted a substantial body of research evidence favoring colorectal cancer screening, much of which had accumulated in the few years preceding the report. Guidelines subsequently published by the American Cancer Society and others2-5 consolidated a national consensus favoring colorectal cancer screening. Medicare began paying for colorectal cancer screening and other payers have followed. National programs to raise public awareness of colorectal cancer prevention have been initiated. Nevertheless, colorectal cancer screening rates in the United States population remain low.6Recognizing that guidelines can become out of date, especially in rapidly evolving fields, the medical societies that sponsored the original guidelines decided that the 1997 guidelines should be reviewed and updated to take into account a substantial body of evidence published in the past 5 years (Table 1). . Table 1. Modifications from prior GI consortium guidelinesScreeningNo rehydration when testing for FOBT.Use of colonoscopy and not barium enema for diagnostic evaluations.Shortened interval for DCBE screening to 5 years in average-risk people.More detailed recommendations for genetic testing in FAP and HNPCC.Reliance on colonoscopy for screening of people with close relatives who have colorectal cancer or adenomatous polyps at age 60 years or 2 affected close relatives.Reliance on colonoscopy for HNPCC screening.Detailed recommendations for genetic testing in FAP and HNPCC.SurveillanceMore use of risk stratification in deciding surveillance intervals after polypectomy; first follow-up colonoscopy in 5 years rather than 3 years for patients at low risk for new adenomas.Reliance on colonoscopy for postpolypectomy surveillance.Reliance on colonoscopy for follow-up surveillance in patients who have had a resection for colorectal cancer.ProcessThe original GI Consortium Panel was comprised of experts in primary care, gastroenterology, surgery, oncology, epidemiology, behavioral science, clinical economics, and nursing, as well as a patient advocate. The panel responsible for the current guidelines was comprised of representatives from the original panel and of the U.S. Multisociety Task Force on Colorectal Cancer, a combined effort of the American College of Gastroenterology, the American Society of Gastrointestinal Endoscopy, the American Gastroenterological Association, and the American College of Physicians/Society of Internal Medicine. This group was asked to review the original guidelines, prepare appropriate revisions with rationale, highlight new evidence since 1997, and suggest research questionsthe answers to which seem critical to progress in colorectal cancer screening and surveillance. Societies with representatives on the panel included the American Academy of Family Practice, American College of Gastroenterology, American College of PhysiciansAmerican Society of Internal Medicine, American College of Radiology, American Gastroenterological Association, American Society of Colorectal Surgeons, and American Society for Gastrointestinal Endoscopy.Appropriate members of the guidelines panel, based on their individual interests and expertise, were assigned 1 or more sections of the guidelines previously published by the GI Consortium. They conducted a rature search on the assigned topic and prepared evidence tables summarizing scientifically strong studies that were relevant to colorectal cancer screening and surveillance. These tables, with associated citations, were circulated to the panel for comments. Then, a meeting was held at which the important new evidence was presented and critiqued. Following this, guidelines were drafted based on the meeting consensus, with an accompanying discussion of the rationale, new evidence (since close of evidence gathering for the earlier guidelines in 1996), and recommendations for future research. The document was then edited by the Panel Co-Chairs (S.J.W., R.H.F.) and the Task Force Chair (D.K.R.) and circulated to the members for comments. The final draft was then circulated to appropriate committees of the sponsoring organizations. The final draft was also reviewed and endorsed by the American Cancer Society.The following recommendations are intended for the U.S. context. Other countries with similar rates of colorectal cancer, clinical practices, resources, and values might also find these guidelines appropriate for their setting.General recommendationsPeople with symptoms or signs that suggest the presence of colorectal cancer or polyps fall outside the domain of screening and should be offered an appropriate diagnostic evaluation (Table 2). . Table 2. Key elements in screening average-risk peopleOffer screening to men and women aged 50 years and olderStratify patients by riskOptions should be offeredFollow-up of positive screening test with diagnostic colonoscopyAppropriate and timely surgery for detected cancersFollow-up surveillance required after polypectomy and surgeryProviders need to be proficientEncourage participation of patientsScreening programs should begin by classifying the individual patients level of risk based on personal, family, and medical history, which will determine the appropriate approach to screening in that person.Men and women at average risk should be offered screening for colorectal cancer and adenomatous polyps beginning at age 50 years.They should be offered options for screening, with information about the advantages and disadvantages associated with each approach, and should be given an opportunity to apply their own preferences in selecting how they should be screened.If the result of a screening test is abnormal, physicians should recommend a complete structural examination of the colon and rectum by colonoscopy (or flexible sigmoidoscopy and double contrast barium enema if colonoscopy is not available).Surveillance with colonoscopy should be considered for patients who are at increased risk because they have been treated for colorectal cancer, have an adenomatous polyp diagnosed, or have a disease that predisposes them to colorectal cancer, such as inflammatory bowel disease.Health care providers who perform the tests should have appropriate proficiency, and the tests should be performed correctly. To achieve these aims, care systems should establish standards and operating procedures.Screening should be accompanied by efforts to optimize the participation of patients and health care providersboth with screening tests and appropriate diagnostic evaluation of abnormal screening test resultsand to remind patients and providers about the need for rescreening at recommended intervals.Risk stratificationClinicians should determine an individual patients risk status well before the earliest potential initiation of screening (typically around age 20 years, but earlier if there is a family history of familial adenomatous polyposis) (Figure 1). Fig. 1. Algorithm for colorectal cancer screening. +, Either colorectal cancer or adenomatous polyp; *, HNPCC = hereditary nonpolyposis colorectal cancer and FAP = familial adenomatous polyposis. *See text.The individuals risk status determines when screening should be initiated and what tests and frequency are appropriate.Risk stratification can be accomplished by asking several questions aimed at uncovering the risk factors for colorectal cancer: Has the patient had colorectal cancer or an adenomatous polyp?Does the patient have an illness (e.g., inflammatory bowel disease) that predisposes him or her to colorectal cancer?Has a family member had colorectal cancer or an adenomatous polyp? If so, how many, was it a first-degree relative (parent, sibling, or child), and at what age was the cancer or polyp first diagnosed?A positive response to any of these questions should prompt further efforts to identify and define the specific condition associated with increased risk. Recommendations for screening people at average riskMen and women at average risk should be offered screening with one of the following options beginning at age 50 years. The rationale for presenting multiple options is that no single test is of unequivocal superiority and that giving patients a choice allows them to apply personal preferences and may increase the likelihood that screening will occur. The strategies are not equal with regard to evidence of effectiveness, magnitude of effectiveness, risk, or up-front costs. Reviewing the rationale section for each screening test (below) will provide clinicians with information that they can use in presenting the relative effectiveness of each test to patients.Fecal occult blood testing Recommendation Offer yearly screening with fecal occult blood test (FOBT) using a guaiac-based test with dietary restriction or an immunochemical test without dietary restriction. Two samples from each of 3 consecutive stools should be examined without rehydration. Patients with a positive test on any specimen should be followed up with colonoscopy.Rationale Testing of 2 samples from each of 3 consecutive stools for the presence of occult blood using a guaiac-impregnated slide test has been shown in 3 randomized controlled trials to reduce the risk of death from colorectal cancer.7-10 Although the sensitivity of a single FOBT is low, in the 30%50% range, a program of repeated annual testing can detect as many as 92% of cancers.7 Offering yearly FOBT with rehydration reduced colorectal cancer deaths by 33% after 13 years; biennial testing reduced colorectal cancer deaths by 15% and 18% after 7.8 and 10 years, respectively, without rehydration8,9 and 21% at 18 years with rehydration.10 People who actually follow through with screening have a greater benefit; a substantial proportion of patients in these trials did not complete the recommended screening. We recommend yearly testing because it is more effective than screening every 2 years. Rehydration is not recommended: although rehydration of the guaiac-based slides increases sensitivity, the readability of the test is unpredictable, and rehydration substantially increases the false positive rate. Newer guaiac-based and immunochemical tests are available that have improved sensitivity and appear to maintain acceptable specificity.11,12 Dietary restrictions during testing are commonly recommended to reduce the false positive rate for the more sensitive guaiac-based tests but are not necessary for the immunochemical and less sensitive guaiac-based tests.Disadvantages of FOBT are that currently available tests for fecal occult blood fail to detect many polyps and some cancers. Also, most people who test positive will not have colorectal neoplasia (have a false positive test result) and thus will undergo the discomfort, cost, and risk of colonoscopy without benefit. Colonoscopy is recommended for all those with a positive FOBT because it was the diagnostic procedure used throughout most of the trials, and because it is substantially more accurate than double contrast barium enemas for the detection of both small cancers and adenomas.13New evidence With longer (18 years) follow-up in the Minnesota trial, FOBT screening every other year was found to reduce colorectal cancer mortality by 21%,10 a rate consistent with the results of the biennial screening in the 2 European trials.8,9 The incidence of colorectal cancer was also reduced in the screened group.14 A systematic review of 3 clinical trials has shown that a restricted diet does not reduce the positivity rate for the older, less sensitive guaiac-based tests and that very restricted diets may reduce compliance rates.15 However, dietary restriction does affect the performance of the more sensitive guaiac-based tests more recently introduced into clinical practice.16-18 Dietary restriction can be confined to red meat alone by waiting 3 days before developing the test.17 One study showed that testing for FOBT at the time of digital rectal examination (office FOBT) has a high positive predictive value for neoplasia, but its sensitivity and specificity are not known.19 A study of screening colonoscopy in people 4049 years old confirmed that colorectal cancers are uncommon in this age group, supporting the recommendation that screening in average risk people begin at age 50 years.20 One national study showed that only 1 in 3 people with a positive FOBT currently undergoes colonoscopy and therefore is in a position to benefit fully from screening.21Sigmoidoscopy Recommendation Offer flexible sigmoidoscopy every 5 years.Rationale Four case-control studies have reported that sigmoidoscopy was associated with reduced mortality for colorectal cancer.22-25 The strongest of these reported that screening sigmoidoscopy reduced colorectal cancer mortality by two thirds for lesions within reach of the sigmoidoscope.22 Colon cancer risk in the area beyond the reach of the sigmoidoscope was not reduced, affirming the validity of this study. A 5-year interval between screening examinations is a conservative choice. It is supported by the observation that a reduction in colorectal cancer deaths related to screening sigmoidoscopy was present up to 10 years from the last screening examination,22 that repeat colonoscopy 5 years after a negative colonoscopy found few instances of advanced neoplasia,26 and follow-up of a cohort of patients after polyp excision showed that development of advanced neoplasia was rare up to 5 years after a negative colonoscopy.27 The interval is shorter than for colonoscopy because flexible sigmoidoscopy is less sensitive than colonoscopy even in the area examined because of the technique and quality of bowel preparation, the varied experience of the examiners performing the procedure, and the effect patient discomfort and spasm may have on depth of sigmoidoscope insertion and adequacy of mucosal inspection. A 10-year interval seems adequate when the examination is performed by a well-trained examiner, either a physician or a nonphysician-endoscopist, in a patient who is well prepared and has been examined up to or near the splenic flexure.The decision to perform colonoscopy after the detection of a neoplasm on flexible sigmoidoscopy is controversial and should be individualized. Factors associated with an increased risk of advanced proximal neoplasia include age 65 years, villous histology in distal adenomas and adenomas 1 cm, multiple distal adenomas, and a positive family history of colorectal cancer.28-30 Whether persons with only a single distal tubular adenoma 1 cm in size are at increased risk for advanced proximal neoplasia remains uncertain. Polyps 1 cm in size detected at flexible sigmoidoscopy should generally be assumed to be adenomas because a very large proportion of these polyps are adenomatous. For polyps 1 cm in size, biopsy will distinguish hyperplastic from adenomatous polyps. Identification of villous elements or high-grade dysplasia, information that may be useful in deciding whether to proceed with colonoscopy, may not be obtainable when the polyp is adenomatous and approaches 1 cm in

温馨提示

  • 1. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
  • 2. 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
  • 3. 本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
  • 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
  • 5. 人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
  • 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
  • 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。

评论

0/150

提交评论